secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001819790-22-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3
-----------------------------------------------------------------------

- Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.
- TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 for Demodex blepharitis; NDA submission H2 2022.
- Cash $175.3M at March 31; completed $71M net equity raise in May; cash runway into at least 2026.
- TP-05 Phase 1b Callisto data expected H2 2022; TP-04 Phase 2 for rosacea planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/0001819790-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000016/tars-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer